307 results match your criteria: "Carbon Dioxide Laser Surgery in Gynecology"
[Value of laser therapy, photodynamic therapy, and follow-up observation in the management of cervical low-grade squamous intraepithelial lesions: a prospective cohort study].
Zhonghua Fu Chan Ke Za Zhi
November 2024
Cervical Disease Center, Obstetrics and Gynecology Hospital of Fudan University, Shanghai200011, China.
To explore the value of CO laser therapy, photodynamic therapy, and follow-up observation in the management of cervical low-grade squamous intraepithelial lesion (LSIL). Women diagnosed with cervical LSIL and high risk human papillomavirus (HR-HPV) infection through colposcopy-guided biopsy from January 1, 2021 to December 31, 2023 were collected. According to a 1∶1 ratio, 107 cases were included in each of the laser treatment, photodynamic therapy, and follow-up groups.
View Article and Find Full Text PDFImpact of colposcopy-guided carbon dioxide laser vaporization therapy on peripheral cervical intraepithelial neoplasia lesions.
Taiwan J Obstet Gynecol
November 2024
Department of Obstetrics and Gynecology, Sapporo Medical University School of Medicine, Sapporo, Japan.
Objective: Laser vaporization is less invasive than conization for cervical intraepithelial neoplasia (CIN). The outcome of laser vaporization for CIN is empirically known to depend on the colposcopic findings, especially localization of the lesion. In this study, we sought to identify factors involved in the outcome of laser vaporization.
View Article and Find Full Text PDFComparative analysis of Paiteling a traditional Chinese medicine (TCM) and CO2 laser therapy for high-risk HPV-associated with LSIL (CIN1) lesions.
Eur J Obstet Gynecol Reprod Biol
November 2024
Department of Gynecology, The First Affiliated Hospital of Wenzhou Medical, University, Ouhai, Zhejiang 325003, China. Electronic address:
Article Synopsis
- This study evaluates the effectiveness of two treatments, Paiteling and CO2 laser therapy, in clearing high-risk human papillomavirus (HR-HPV) in patients with low-grade cervical lesions over a two-year period.
- A total of 558 patients were analyzed, with 239 receiving Paiteling and 319 receiving CO2 laser therapy; results were monitored at 3, 6, 12, and 24 months post-treatment.
- The findings indicate that Paiteling had a significantly faster median HR-HPV clearance time and higher long-term negative rates compared to CO2 laser therapy, with both treatments showing minimal reinfection rates.
Understanding the Benefits of CO Laser Treatment for Vulvovaginal Atrophy.
Medicina (Kaunas)
June 2024
Clinic for Gynecology and Obstetrics, Narodni Front, Kraljice Natalije 62, 11000 Belgrade, Serbia.
Article Synopsis
- Postmenopausal vaginal discomfort, often caused by vulvovaginal atrophy (VVA), leads to symptoms like dryness, itching, and pain during sex, affecting women’s sexual health.
- A pilot study involving 84 sexually active postmenopausal women aimed to evaluate the effectiveness of a micro-ablative fractional CO laser in relieving VVA symptoms and enhancing sexual function.
- Results showed significant improvements post-treatment, with nearly all participants returning to normal vaginal health scores and higher sexual function scores, indicating that the fractional CO laser is a promising treatment for VVA.
Cold Knife Versus Carbon Dioxide for the Treatment of Preinvasive Cervical Lesion.
Medicina (Kaunas)
June 2024
Department of Clinical and Experimental Sciences, University of Brescia, 25136 Brescia, Italy.
Article Synopsis
- Cervical cancer poses a major health risk for younger women, and tools like cold knife (CK) and carbon dioxide (CO) laser conization are used to treat pre-invasive lesions with the intent to cure incidental cervical cancer cases.
- A study involving 1,270 women showed that CO laser conization had a significantly lower rate of positive margins compared to CK conization (4.3% vs. 13.3%).
- Both techniques demonstrated similar oncological safety in cases of incidental cervical cancer diagnosis, with no recurrences noted after an average follow-up period of 53 months, and CO laser conization generally proved more effective at achieving clean margins.
Safety and efficacy of non-ablative CO laser treatment of vulvo-vaginal atrophy in women with history of breast cancer.
Arch Gynecol Obstet
April 2024
Gynecology and Physiopathology of Human Reproduction, IRCCS Azienda Ospedaliero-Universitaria of Bologna, Via Massarenti 13, 40138, Bologna, Italy.
Article Synopsis
- Breast cancer survivors experience significant vulvo-vaginal atrophy (VVA), and the study aims to evaluate the effectiveness and safety of non-ablative CO laser therapy as a treatment option for these women.
- The study involved 26 women who underwent three sessions of laser therapy, with assessments of VVA symptoms and sexual function at multiple time points, showing significant improvements in objective and subjective measures of VVA.
- Results indicated that the laser treatment was effective across different initial conditions, with no major side effects reported, making it a viable option for enhancing sexual function and alleviating VVA symptoms in breast cancer survivors.
Different effects of CO laser and estrogen treatment on vaginal mucosa microbiota and function in genitourinary syndrome of menopause patients.
J Obstet Gynaecol Res
April 2024
Department of Obstetrics and Gynecology, The Fifth Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.
Article Synopsis
- The study aimed to evaluate the impact of CO laser treatment and estrogen therapy on the vaginal microbiota of women suffering from genitourinary syndrome of menopause (GSM).
- Sixty-four patients were divided into three groups (estrogen, CO laser, and control), with treatments assessed after 3 and 12 months, revealing both treatments reduced alpha diversity in vaginal flora and improved vaginal health scores.
- While both treatments benefitted patients, CO laser therapy showed more significant long-term effectiveness, particularly in increasing type III collagen and maintaining symptom improvement compared to estrogen therapy.
Combined clinical and radiological remission of rectovaginal fistulas using fractional CO2 vaginal laser: a case series and medium-term follow-up.
BMC Res Notes
December 2023
Department of Gynecology, Universidade Federal de São Paulo, São Paulo, Brazil.
Article Synopsis
- There is currently no consensus on the best treatment for rectovaginal fistula (RVF), but the fractional CO2 laser is being explored as a potential solution.
- A study conducted at Juiz de Fora University Hospital involved 15 patients with confirmed RVF, who underwent five sessions of fractional CO2 laser therapy to evaluate its effectiveness and safety.
- Results showed that 67.7% of patients experienced clinical remission of RVF symptoms, improvements in sexual function, and significant symptom relief, suggesting CO2 fractional laser therapy is a promising option for RVF management.
Physical energies for the management of genitourinary syndrome of menopause: An overview of a systematic review and network meta-analysis.
Int J Gynaecol Obstet
July 2024
Health Sciences Postgraduate Program, Federal University of Rio Grande do Norte (UFRN), Natal, Rio Grande do Norte, Brazil.
Article Synopsis
- Energy-based treatments, like lasers and radiofrequency, are examined for their effectiveness and safety in alleviating symptoms of genitourinary syndrome of menopause (GSM) among postmenopausal women.
- A review of nine studies, including four randomized controlled trials, revealed that certain treatments (e.g., Premarin, conjugated estrogens, carbon dioxide laser) significantly improved sexual function compared to placebo, though some studies had a high risk of bias.
- The overall confidence in the findings was low due to methodological concerns, highlighting the need for more rigorous and blinded clinical trials to strengthen the evidence for these treatments.
Vaginal CO laser therapy for genitourinary syndrome in breast cancer survivors-VagLaser study protocol: a randomized blinded, placebo-controlled trial.
BMC Cancer
November 2023
Department of Clinical Medicine, Aarhus University, Aarhus, Denmark.
Article Synopsis
- Vaginal CO laser therapy is being studied as a treatment for genitourinary syndrome of menopause, especially in breast cancer survivors who face challenges with traditional hormonal treatments.
- The research includes various sub-studies focused on effectiveness, including dose response and placebo control, with primary outcomes looking at vaginal dryness and secondary outcomes considering pain, urinary symptoms, and changes in microbiota.
- The study aims to determine the best treatment regimen and the impact of repeated treatments, marking the first investigation into how vaginal laser therapy affects vaginal and urine microbiota in this population.
Fractional CO laser treatment for women with stress predominant urinary incontinence: a randomized controlled trial.
Int Urogynecol J
November 2023
Department of Obstetrics & Gynaecology, Faculty of Medicine, Khon Kaen University, 123 Mittraphap Highway, Muang Khon Kaen, Khon Kaen, 40002, Thailand.
Article Synopsis
- This study aimed to compare the effectiveness of vaginal CO laser treatment against a sham (placebo) treatment for women with stress urinary incontinence (SUI) over a 3-month period.
- In a randomized controlled trial with 59 participants, both groups showed significant improvements in urinary incontinence scores, but there were no meaningful differences between the CO laser group and the sham group.
- The findings suggest that the improvement in SUI symptoms may be due to pelvic floor muscle training rather than the CO laser intervention, indicating no added benefit from the laser treatment itself.
Long-term clinical and histological safety and efficacy of the CO laser for treatment of genitourinary syndrome of menopause: an original study.
Climacteric
December 2023
School of Medicine, Vita-Salute San Raffaele University, Milan, Italy.
Article Synopsis
- The study investigated the effects of repeated microablative fractional CO laser treatments on the vaginal mucosa of 15 postmenopausal women experiencing genitourinary syndrome, using various validated questionnaires and histological examinations.
- Findings showed significant improvements in vaginal health and sexual function, as well as a decrease in urinary symptoms four weeks after treatment, along with positive tissue changes like increased epithelial thickness and cell layers.
- This research is the first to demonstrate that annual laser treatments can lead to lasting tissue regeneration without causing fibrosis, indicating potential long-term benefits for women undergoing similar therapies.
Near-infrared and hysteroscopy-guided robotic excision of uterine isthmocele with laser fiber: a novel high-precision technique.
Fertil Steril
November 2023
Division of Reproductive Endocrinology and Infertility, Department of Obstetrics, Gynecology, and Reproductive Biology, Brigham & Women's Hospital, Harvard Medical School, Boston, Massachusetts.
Article Synopsis
- A novel high-precision technique for robotic excision of uterine isthmocele is introduced, utilizing carbon dioxide laser fiber under hysteroscopic and near-infrared guidance.
- The case involves a 36-year-old woman with secondary infertility due to a large cesarean scar defect identified via imaging, leading to a decision for surgical intervention.
- The surgical procedure included the use of laser dissection combined with near-infrared technology for enhanced visualization, ultimately leading to the successful removal of the isthmocele.
Nonestrogen Therapies for Treatment of Genitourinary Syndrome of Menopause: A Systematic Review.
Obstet Gynecol
September 2023
Division of Female Pelvic Medicine & Reconstructive Surgery, Department of Obstetrics & Gynecology, University of Texas at San Antonio, San Antonio, the Division of Female Pelvic Medicine & Reconstructive Surgery, Department of Obstetrics & Gynecology, University of Texas Southwestern Medical Center, Dallas, and the Division of Female Pelvic Medicine and Reconstructive Surgery, Department of Obstetrics & Gynecology, Baylor College of Medicine, Houston, Texas; the Division of Female Pelvic Medicine and Reconstructive Surgery, Department of Obstetrics & Gynecology, Wayne State University School of Medicine, Detroit, Michigan; the Division of Urogynecology, ProHealth Women's Services, Waukesha Memorial Hospital, Waukesha, Wisconsin; the Center for Evidence Synthesis in Health, Brown University School of Public Health, Providence, Rhode Island; the Departments of Obstetrics and Gynecology and Urology, MedStar Washington Hospital Center, Georgetown University School of Medicine, and the Division of Female Pelvic Medicine and Reconstructive Surgery, Department of Obstetrics & Gynecology, Howard University College of Medicine, Washington, DC; and the Salinas Valley Memorial Healthcare System, Salinas, California.
Article Synopsis
- The objective of the review was to evaluate nonestrogen therapies for treating genitourinary syndrome of menopause (GSM) and develop clinical practice guidelines.
- The study analyzed data from various research databases and included 136 studies focused on seven specific therapies that are currently available.
- The findings suggest that most nonestrogen treatments are effective for GSM symptoms, with some therapies showing comparable or better results than estrogen or placebo, although there is a lack of comparative data among nonestrogen options.
Efficacy and safety of carbon dioxide laser therapy compared with sham for genitourinary syndrome of menopause management: a meta-analysis of randomized clinical trials.
Menopause
September 2023
Department of Obstetrics and Gynecology, Bhumi Mother and Child Clinic, Magelang, Central Java, Indonesia.
Article Synopsis
- CO 2 laser therapy shows potential benefits for treating genitourinary syndrome of menopause (GSM), particularly in reducing symptoms and improving patient satisfaction compared to a sham treatment.
- The meta-analysis included six randomized clinical trials and found that CO 2 laser treatment significantly lowered scores on the Vaginal Assessment Scale and Urinary Distress Inventory short form.
- While the therapy was associated with mild adverse events, no serious side effects were reported, indicating a good safety profile, but further research with larger sample sizes is recommended to validate these findings.
Vaginal laser therapy for GSM/VVA: where we stand now - a review by the EUGA Working Group on Laser.
Climacteric
August 2023
Department of Obstetrics and Gynecology, Del Ponte Hospital, University of Insubria, Varese, Italy.
Article Synopsis
- - Vulvovaginal atrophy (VVA) is a common condition caused by decreased estrogen after menopause, leading to symptoms in the genital and urinary areas, and is better referred to as genitourinary syndrome of menopause (GSM).
- - Treatment often requires long-term management, starting with lubricants or moisturizers and moving to low-dose vaginal estrogens if necessary; breast cancer survivors may face additional challenges due to hormonal therapy restrictions.
- - Recent studies show that non-ablative erbium:YAG and fractional microablative CO vaginal lasers are effective and safe options for improving vaginal health and alleviating GSM symptoms in postmenopausal women and breast cancer survivors.
Effect evaluation and influencing factor analysis of vaginal carbon dioxide laser in the treatment of stress urinary incontinence.
Lasers Med Sci
July 2023
Department of Obstetrics and Gynecology, Affiliated Hospital of Nantong University, Nantong, 226001, China.
Article Synopsis
- A study evaluated the effectiveness of transvaginal carbon dioxide laser therapy for treating stress urinary incontinence in 46 female patients over 16 months.
- Patients reported a notable improvement in symptoms, as seen in reduced urine leakage and lower scores on the ICI-Q-SF questionnaire, with statistically significant results (P < 0.05).
- The research concluded that this laser treatment is safe and effective for mild to moderate cases, with better outcomes linked to less severe urinary leakage prior to treatment.
The effect of CO laser therapy on vaginal microcirculatory parameters in an animal model for genitourinary syndrome of menopause.
Neurourol Urodyn
August 2023
Department of Obstetrics and Gynecology, Amsterdam UMC Location University of Amsterdam, Amsterdam, The Netherlands.
Article Synopsis
- - The study investigates the efficacy of CO laser therapy for treating vaginal atrophy due to genitourinary syndrome of menopause (GSM) using an animal model of 25 ewes, where 20 underwent ovariectomy to simulate menopause.
- - Monthly treatments of CO laser and vaginal estrogen were compared, with estrogen showing significant improvements in capillary loops and epithelial thickness, while CO laser therapy did not show any changes in microcirculatory parameters.
- - The research suggests that different treatment parameters may be needed for effective application in humans, given the anatomical differences, particularly the thinner vaginal epithelium in ewes compared to that in humans.
Comparison of Er:YAG and CO laser therapy for women with stress urinary incontinence.
Lasers Surg Med
September 2023
Department of Obstetrics and Gynecology, Hualien Tzu Chi Hospital, Buddhist Tzu Chi Foundation, and Tzu Chi University, Hualien, Taiwan, ROC.
Article Synopsis
- - The study aimed to compare the effectiveness of Er:YAG and CO laser therapies in treating female stress urinary incontinence (SUI), involving 139 women divided into four treatment groups based on the type and number of therapy sessions.
- - Results showed significant improvement in urinary incontinence symptoms for all groups, with the Er:YAG laser proving more effective than the CO laser, particularly after three months post-treatment.
- - The conclusion suggests that vaginal laser therapy, especially the Er:YAG type, could be a promising alternative for treating mild to moderate SUI, but more extensive research is necessary to validate these findings.
The European Society of Gynaecological Oncology (ESGO), the International Society for the Study of Vulvovaginal Disease (ISSVD), the European College for the Study of Vulval Disease (ECSVD), and the European Federation for Colposcopy (EFC) consensus statement on the management of vaginal intraepithelial neoplasia.
Int J Gynecol Cancer
April 2023
Department of Obstetrics & Gynecology, University of Iowa, Iowa City, Iowa, USA.
Article Synopsis
- The European Society of Gynaecological Oncology and other organizations created consensus statements to enhance care for patients with vaginal intraepithelial neoplasia (VaIN).
- Treatment for VaIN depends on the lesion's grade, with follow-ups for low-grade VaIN (VaIN 1) and treatment required for high-grade (VaIN 2-3), highlighting that management should be personalized.
- Surgical excision is the primary treatment; alternatives like CO laser and topical agents exist, with imiquimod showing the best outcomes, while brachytherapy is suited for specific cases, and consistent follow-up is essential due to the recurring nature of VaIN.
The European Society of Gynaecological Oncology (ESGO), the International Society for the Study of Vulvovaginal Disease (ISSVD), the European College for the Study of Vulval Disease (ECSVD), and the European Federation for Colposcopy (EFC) Consensus Statement on the Management of Vaginal Intraepithelial Neoplasia.
J Low Genit Tract Dis
April 2023
Department of Obstetrics & Gynecology, University of Iowa, Iowa City, IA.
Article Synopsis
- The consensus statements developed by ESGO, ISSVD, ECSVD, and EFC aim to enhance care for patients with vaginal intraepithelial neoplasia (VaIN), outlining management strategies based on lesion grade.
- For low-grade VaIN (VaIN 1), follow-up is usually sufficient, while high-grade VaIN (VaIN 2-3) requires treatment, with surgical excision being the primary method if invasion is suspected.
- Treatments like CO2 laser and topical agents, especially Imiquimod, are effective, but surgical options are often necessary for cases post-hysterectomy, and patients should be closely monitored due to the risk of recurrence.
Randomized clinical trial with fractional CO laser and Clobetasol in the treatment of Vulvar Lichen Sclerosus: a clinic study of feasibility.
BMC Res Notes
March 2023
Public Health Department, Federal University of Juiz de Fora, Juiz de Fora, MG, 36036-110, Brazil.
Article Synopsis
- The study aimed to compare the effectiveness of fractional CO2 laser treatment with Clobetasol for vulvar conditions among 20 women at a Brazilian university hospital.
- Results showed no significant differences in clinical or anatomical characteristics between the two treatments, but patients in the laser group reported higher satisfaction three months after treatment.
- The laser therapy was well-received and showed potential as an effective treatment option, despite increased instances of telangiectasia post-treatment.
5-aminolevulinic acid photodynamic therapy combined with carbon dioxide laser therapy is a safe and effective treatment for vaginal intraepithelial neoplasia.
Photodiagnosis Photodyn Ther
March 2023
Department of Gynecology, The First Affiliated Hospital of Bengbu Medical College, No.287, Changhuai Road, Bengbu, Anhui Province 233000, China.
Article Synopsis
- - This study investigates the effectiveness of combining 5-aminolevulinic acid photodynamic therapy (5-ALA-PDT) with CO2 laser therapy to treat vaginal intraepithelial neoplasia (VaIN), a precursor to vaginal cancer.
- - Researchers analyzed data from 40 VaIN patients, comparing treatment outcomes such as cure rates and human papillomavirus (HPV) clearance after different therapies, and found significant differences in HPV clearance but not in overall cure rates after 12 months.
- - The combination therapy was found to be safe with fewer adverse effects compared to CO2 laser treatment alone, suggesting that adding 5-ALA-PDT may improve patient outcomes for VaIN treatment.
Re: CO Surgical Laser for Treatment of Stress Urinary Incontinence in Women: A Randomized Controlled Trial.
Eur Urol
April 2023
Department of Obstetrics and Gynecology, EOC-Beata Vergine Hospital, Mendrisio, Switzerland; Faculty of Biomedical Sciences, Università della Svizzera Italiana, Lugano, Switzerland. Electronic address:
Combining Sclerotherapy with CO Laser Ablation for the Laparoscopic Management of Large Endometrioma: Advantages and Pitfalls.
J Minim Invasive Gynecol
March 2023
Department of Obstetrics and Gynecology, Lausanne University Hospital, Lausanne, Switzerland (Dr. Pluchino).
Article Synopsis
- - The study aimed to explore the effectiveness of a 2-step laparoscopic procedure to manage large endometriomas while preserving ovarian reserve, particularly in a 22-year-old woman with severe dysmenorrhea and a 10 cm endometrioma.
- - The first step involved laparoscopic ethanol sclerotherapy to empty and fill the endometrioma cavity with ethanol, followed by a 12-week interval before the second step, which used CO laser ablation to remove remaining endometrioma tissue.
- - The results indicated that this combined laparoscopic technique is feasible, but further research is necessary to compare its long-term benefits against traditional cystectomy methods and to better understand the potential risks of ethanol-induced ovarian fibrosis.